NCT07620574Enrolling by invitationPhase 3
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 5000 (estimated)
- First submitted
- 27 May 2026
- Start date
- 30 Jul 2026
- Primary completion date
- 31 May 2030
- Lead sponsor
- Exelixis
- Diseases
- Prostate cancer, Thyroid cancer, Neuroendocrine tumours, Kidney cancer, Pancreatic cancer, Colorectal cancer, Liver and biliary tract cancer, Childhood cancers
- NCT number
- NCT07620574
- EU CT number
- 2026-525795-26-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 5000
- From 30 Jul 2026 to the primary completion date, 31 May 2030
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with any anticancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study.
- Concurrent participation in any therapeutic clinical trial (other than the parent study).
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Other illness
- Study treatment is commercially marketed in the participant's country for the participant-specific disease and is accessible to the participant.
Other
- Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in this extension study.
- Permanent discontinuation of all study treatment(s) for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in this long-term extension study (if applicable).
Who the study is looking for
- Eligible to continue receiving the study treatment in the parent study (that is, has not met parent study discontinuation/withdrawal criteria).
- Continuing to derive clinical benefit from the study treatment at the time of transition from the parent study as assessed by the investigator.
- Able to comply with the long-term extension study protocol as determined by the investigator.
- Able to receive the first dose of study treatment in this extension study within the specified treatment interruption window allowed by the parent study.
Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| New York Cancer and Blood Specialists Coordinator of this site? Confirm its status | Bay Shore | United States | Unknown status |
| The University of Texas MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| Greater Dayton Cancer Center Coordinator of this site? Confirm its status | Kettering | United States | Unknown status |
| The West Clinic Coordinator of this site? Confirm its status | Memphis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.